| Today’s Big NewsOct 17, 2023 |
| By Annalee Armstrong Biopharmas love to break the news of an M&A deal with a splashy number. Commercial milestones can represent as much as 40% of the so-called earnout potential for a deal—adding up to about $25 billion in potential. But how much of that is actually paid out in the end? |
|
|
|
By Angus Liu Thanks to a new FDA approval for Merck's Keytruda, a continuous immunotherapy regimen around surgery is now available for patients with early-stage non-small cell lung cancer. The drug's label already includes an overall survival win from a key trial. |
By Angus Liu A drug combination from Johnson & Johnson outperformed AstraZeneca’s Tagrisso in slowing the worsening of newly diagnosed lung cancer. But it’ll take more than a tumor progression win to dethrone the EGFR king. |
By Conor Hale Johnson & Johnson MedTech expects to take a $250 million revenue hit before 2026 as it restructures its orthopedics businesses and exits low-performing markets. |
|
November 14-15, 2023 | Free Virtual Event The Fierce Diversity, Equity, and Inclusion Forum is back again this year and better than ever. We are collaborating with our Fierce Healthcare Editorial Team to expand the topics and audience for this exciting program across two days. Providing a wide range of strategies and best practices for pharma and biotech companies looking to improve their diversity efforts across all areas of their business. Save your seat now!
|
|
By Eric Sagonowsky Even after touting revenue and profit growth in the third quarter, Johnson & Johnson is busy getting ready for the looming loss of Stelara's exclusivity. |
By Fraiser Kansteiner With the U.K. working to tweak the Statutory Scheme for branded medicines, the Association of the British Pharmaceutical Industry is making its discontent known—and it’s managed to rally more than 20 major drugmakers to its cause. |
By Conor Hale Thermo Fisher Scientific is putting down a premium to acquire Olink, a Swedish provider of proteomics analysis equipment and services for tracking down biomarkers. |
By Nick Paul Taylor Gilead wants first dibs on all Assembly Biosciences’ programs. Rather than buy the viral disease biotech, Gilead is paying $100 million upfront for opt-in rights on all Assembly’s current and future programs. |
By Zoey Becker Influential trade group PhRMA—plus hundreds of drugmakers, leaders and investors—are urging the Supreme Court to overturn a restrictive ruling on the abortion pill mifepristone. In SCOTUS filings, the industry representatives said the ruling undermines the FDA's authority. |
By James Waldron Roche has signed its second molecular glue deal in a month, this time paying $50 million upfront to Monte Rosa Therapeutics for the use of its QuEEN platform to target cancer and neurological diseases previously considered out of reach. |
By Nick Paul Taylor Evelo Biosciences’ last roll of the dice has come up snake eyes. After seeing its lead candidate flounder in the clinic, the biotech has revealed its next-generation asset performed worse than placebo in a phase 2 psoriasis trial, prompting it to start searching for strategic alternatives. |
By Conor Hale VedaBio debuted with a CRISPR platform to detect an array of molecules at room temperature in less than a minute. |
Fierce podcastsDon’t miss an episode |
| | In this episode of "The Top Line," Fierce Biotech's Annalee Armstrong engages in a conversation with Howard Fillit, M.D., an expert in the field of Alzheimer's research and the co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation. They delve into the pioneering work being done in Alzheimer's research, discuss the latest breakthroughs, and explore the ongoing efforts to combat this complex disease. |
|
|---|
|
|
|
Thursday, November 9, 2023 | 2pm ET / 11am PT Join us for this webinar to explore the transformative power of decentralized clinical trials. Learn how automation is reshaping the landscape of clinical development, empowering life sciences professionals to streamline processes, reduce costs, and accelerate drug development timelines. Register now.
|
|
| WhitepaperUncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
| WhitepaperFrom trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
| eBookLearn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| WhitepaperUncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
| WebinarEmbark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
| WhitepaperEconomic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
| WhitepaperFrom Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| |
|
